Connect Doses Asthma Patients in Global Trial of Interleukin Antibody
May 12, 2021 at 05:50 AM EDT
Connect Biopharma, a Taicang-San Diego company, has dosed the first patient in a global Phase II trial testing CBP-201 in adults with moderate-to-severe persistent asthma who have Type 2 inflammation. CBP-201 is an interleukin-4 receptor alpha (IL-4Rα) antibody that has already started trials for atopic dermatitis and is also in development to treat chronic rhinosinusitis with nasal polyps. The asthma trial will administer two doses of CBP-201 to 300 patients in the US , China , EU and other sites. More details.... Stock Symbol: (NSDQ: CNTB) Share this with colleagues: // //